Evidence map›Paper›PMID 35611695›Full record

ArticleCirculation research2022

Targeting Adiponectin Receptor 1 Phosphorylation Against Ischemic Heart Failure.

Di Zhu, Zhen Zhang, Jianli Zhao, Demin Liu, Lu Gan, Wayne Bond Lau, Dina Xie, Zhijun Meng, Peng Yao, Jumpei Tsukuda and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Unveiling the roles of CTRP family in cardiac remodeling.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Di ZhuDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Zhen ZhangDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Jianli ZhaoDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Demin LiuDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Lu GanDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).ORCID 0000-0001-8665-2760
Wayne Bond LauDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Dina XieDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Zhijun MengDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Peng YaoDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Jumpei TsukudaDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Theodore A ChristopherDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Bernard L LopezDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Erhe GaoDepartment of Cardiovascular Sciences, Center for Translational Medicine, Temple University, Philadelphia, PA (E.G., W.J.K.).
Walter J KochDepartment of Cardiovascular Sciences, Center for Translational Medicine, Temple University, Philadelphia, PA (E.G., W.J.K.).
Yajing WangDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Xin-Liang MaDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (D.Z., Z.Z., J.Z., D.L., L.G., W.B.L., D.X., Z.M., P.Y., J.T., T.A.C., B.L.L., Y.W., X.-L.M.).
Thomas Jefferson University · USTemple University · US

Funding

Targeting Adiponectin for Cardioprotection in the Ischemic HeartR01HL096686 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG, WANG, YAJING · 2010 to 2024
$4.7M
Cav-3 in Diabetic Myocardial Injury Following Ischemia/ReperfusionR01HL123404 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG · 2015 to 2023
$2.7M
Dysregulated Adiponectin Transmembrane Signaling in Diabetic CoronaryVascular Injury and Heart FailureR01HL157495 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WANG, YAJING · 2022 to 2025
$2.3M
Critical Role of Small Extracellular Vesicles in Diabetic Coronary VascularDysfunction and Diabetic Ischemic Heart Failure effortsR01HL158612 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WANG, YAJING · 2021 to 2024
$1.5M
Vevo 3100 ultrasound scanner and PV loop systemS10OD030483 · OD · THOMAS JEFFERSON UNIVERSITY · PI FORSBERG, FLEMMING · 2021 to 2021
$747k
Cav-3 in Diabetic Myocardial Injury Following Ischemia/ReperfusionR56HL123404 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI MA, XIN-LIANG · 2014 to 2014
$388k
NHLBI NIH HHS R01 HL096686NHLBI NIH HHS R01 HL123404NHLBI NIH HHS R01 HL157495NHLBI NIH HHS R01 HL158612NHLBI NIH HHS R56 HL123404NIH HHS S10 OD030483
6 · The paper itself

Abstract

backgroundDespite significantly reduced acute myocardial infarction (MI) mortality in recent years, ischemic heart failure continues to escalate. Therapeutic interventions effectively reversing pathological remodeling are an urgent unmet medical need. We recently demonstrated that AdipoR1 (APN [adiponectin] receptor 1) phosphorylation by GRK2 (G-protein-coupled receptor kinase 2) contributes to maladaptive remodeling in the ischemic heart. The current study clarified the underlying mechanisms leading to AdipoR1 phosphorylative desensitization and investigated whether blocking AdipoR1 phosphorylation may restore its protective signaling, reversing post-MI remodeling.

methodsSpecific sites and underlying molecular mechanisms responsible for AdipoR1 phosphorylative desensitization were investigated in vitro (neonatal and adult cardiomyocytes). The effects of AdipoR1 phosphorylation inhibition upon APN post-MI remodeling and heart failure progression were investigated in vivo.

resultsAmong 4 previously identified sites sensitive to GRK2 phosphorylation, alanine substitution of Ser

conclusionsSer

Indexed as

Heart FailureMyocardial InfarctionMyocardial Reperfusion InjuryAdiponectinAnimalsHumansIschemiaMiceMice, KnockoutMyocytes, CardiacPhosphorylationReceptors, AdiponectinAdiponectinadiponectin receptor 1, mouseReceptors, Adiponectinadipokinesanimalscell deathendocytosisheart failure

Identifiers

PMID35611695
PMCPMC9308652
OpenAlexW4281489143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.